One nanomedicine that received clinical approval is pegaptanib (brand name Macugen, OSI Pharmaceuticals), an anti-VEGF aptamer conjugated with branched polyethylene glycol for the treatment of AMD (Farjo et Ma 2010). This evidence concerns the gene VEGFA and age-related macular degeneration.